Skip directly to site content Skip directly to search


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tickborne Diseases of the United States


Section Navigation
			
			CDC Home


Facebook
        Twitter
        LinkedIn
        Syndicate





Colorado Tick Fever					minus icon
                Contents
			HomeTick IDOverview of Tickborne DiseasesLyme DiseaseTickborne Relapsing Fever (TBRF)Hard Tick Relapsing FeverAnaplasmosisEhrlichiosisRocky Mountain Spotted FeverRickettsia parkeri RickettsiosisTularemiaBabesiosisHeartland and Bourbon Virus DiseasesColorado Tick FeverPowassan Virus DiseaseTickborne Diseases AbroadTick Bites/PreventionLyme Disease Prophylaxis After Tick Bite					Related Pages
										AgentColorado tick fever virusWhere FoundThe geographic range of Colorado tick fever virus includes the Western United States, primarily Colorado, Utah, Montana, and Wyoming. Although rare, the virus can also be transmitted from person-to-person via blood transfusion.Colorado Tick Virus bloodsmearIncubation Period1–14 daysSigns and SymptomsFever, chills, headache, myalgias, and lethargy
~50% of patients have a biphasic illness with symptoms remitting after 2 to 4 days, but then recurring 1 to 3 days later.
Conjunctival injection, pharyngeal erythema and lymphadenopathy may be present.
Maculopapular or petechial rash in <20% of patients
Prolonged convalescence characterized by weakness and fatigue is common in adults.
Life-threatening complications and death are rare and usually associated with disseminated intravascular coagulation or meningoencephalitis in children.General Laboratory FindingsLeukopenia
Moderate thrombocytopeniaLaboratory DiagnosisPreliminary diagnosis of Colorado tick fever (CTF) is based on signs and symptoms, places and dates of travel, activities, and history of potential tick exposure. Acute samples should be tested by reverse-transcriptase polymerase chain reaction (RT-PCR) to detect viral RNA as antibody production is delayed until 14–21 days after onset of symptoms.**Note:** CSF, cerebrospinal fluid; CNS, central nervous systemCTF Testing
Timing of specimen collection
Specimens
Preferred Test<14 days after symptom onset
Serum (CSF if suspected CNS involvement)
RT-PCR for viral RNA≥14 days after symptom onset
Serum (CSF if suspected CNS involvement)
Antibody testing*; consider RT-PCR for samples from days 14-21
*If possible, acute and convalescent samples, collected at least 2 weeks apart, with the convalescent sample collected at least 3 weeks after symptom onset, should be obtained to look for seroconversion or a 4-fold rise in antibody titers typically using a plaque reduction neutralization test (PRNT).**Note:** CTF testing is available at some commercial and state health department laboratories and at CDC. Contact your state or local health department for assistance with diagnostic testing. CTF cases are reportable to local public health authorities in certain states.TreatmentNo specific antiviral treatment is available. Patients with suspected CTF should receive supportive care as appropriate. Patients with confirmed CTF should defer blood and bone marrow donation for at least 6 months after recovery.ReferencesBrackney MM, Marfin AA, Staples JE, et al. Epidemiology of Colorado tick fever in Montana, Utah, and Wyoming, 1995–2003. *Vector Borne Zoonotic Dis* 2010;10:381–385.
Centers for Disease Control and Prevention. West Nile virus and other nationally notifiable arboviral diseases—United States, 2016. *MMWR* 2018; 67(1);13-17.
Staples JE, Fischer M. Coltiviruses (Colorado Tick Fever). In: *Principles and Practice of Pediatric Infectious Diseases*, 5th edition. Eds: Long SS, Prober CG, Fischer M. Elsevier 2018:1119–1121.
Goodpasture HC, Poland JD, Francy DB, et al. Colorado tick fever: clinical, epidemiologic, and laboratory aspects of 228 cases in Colorado in 1973–1974. *Ann Intern Med* 1978;88:303–310.
Kadkhoda K, Semus M, Jelic T, Walkty A. Case report: a case of Colorado tick fever acquired in southwestern Saskatchewan. *Am J Trop Med Hyg.* 2018;98:891–893.
Lambert AJ, Kosoy O, Velez JO, et al. Detection of Colorado Tick Fever viral RNA in acute human serum samples by a quantitative real-time RT-PCR assay. *J Virol Methods* 2007;140:43–48.
McDonald E, George D, Rekant S, et al. Notes from the field: Investigation of Colorado tick fever virus disease cases — Oregon, 2018. *Morb Mortal Wkly Rep.* 2019;68:289–290.
Romero JR, Simonsen KA. Powassan encephalitis and Colorado tick fever. *Infect Dis Clin North Am* 2008;22:545–559.
Williamson BN, Fischer RJ, Lopez JE, et al. Prevalence and strains of Colorado tick fever virus in Rocky Mountain wood ticks in the Bitterroot Valley, Montana. *Vector Borne Zoonotic Dis.*2019;19:694–702.
Yendell SJ, Fischer M, Staples JE. Colorado tick fever in the United States, 2002-2012. *Vector Borne Zoonotic Dis* 2015;15:311–316.Top of Page
									PrevHeartland and Bou...
			NextPowassan Virus Di...
							
					
						Page last reviewed:  August 5, 2022					Content source: 	Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD) homeTickborne Diseases of the United StatesTick IDOverview of Tickborne DiseasesLyme DiseaseTickborne Relapsing Fever (TBRF)Hard Tick Relapsing FeverAnaplasmosisEhrlichiosisRocky Mountain Spotted Fever*Rickettsia parkeri*RickettsiosisTularemiaBabesiosisHeartland and Bourbon Virus DiseasesColorado Tick FeverPowassan Virus DiseaseTickborne Diseases AbroadTick Bites/PreventionLyme Disease Prophylaxis After Tick Bite


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue